Developing a drug that targets cancer cells while avoiding healthy ones is the goal of many researchers around the world.
Up until now they’ve had little success.
But one scientist and doctor has adopted a rather different approach.
He's using the same standard chemotherapy that aggressively targets tumors, but in addition he employs an antidote that protects normal, healthy cells.
Early results indicate it works. And you won’t be surprised to learn the mainstream medical system tried to shoot it down. They don’t want a fast, easy cure for cancer.
If you feel you MUST choose the "poison" approach to get rid of cancer, you may want to consider doing it this way. . .
Continued below...
So Totally Different, It's US PATENTED! Finally, a totally new approach to ending your prostate problems that really works. It doesn't matter what prescriptions or prostate supplements you may have tried. These 122 newly-researched bio-active, phytonutrient messengers represent a totally new approach to ending your got-to-go prostate problems. This is such a paradigm shift in solving prostate problems that its protected by a US Patent. Nobody else has got them! Nor will anyone else ever be able to get these powerful, proven prostate healers. This is a genuine game-changer for every man who's still making night-time bathroom runs! If that's you. . .here's some life-changing news for you! Just click here and end your got-to-go prostate problems forever. Link not working? Simply copy and paste the link below into your browser: http://www.on2url.com/app/adtrack.asp? |
Dr. Kenneth Matsumara calls his method Side Effect-Free, Neutrophil-Potentiated Chemotherapy – SEF Chemo, for short. He pronounces the latter "safe chemo."
Results in late stage cancers have been astounding so far.
One of America’s most promising medical researchers, Dr. Matsumara began his career in medical research in 1959 at the age of 13. That’s not a typo. Amazingly, he published a paper on a new skin-grafting technique two years later.
In 1962 he became the youngest person to be awarded a research grant from the American Lung Association. A renowned biologist at the University of California took the youngster under his wing while he was still attending high school.
Dr. Matsumara has been licensed to practice medicine since 1971 and is the director of a research facility - The Alin Foundation - at Berkeley, California.
His early promise was fulfilled with the invention of a bio-artificial liver to sustain patients suffering liver failure. This was named as one of Time magazine's Inventions of the Year in 2001.
Other inventions include a bio-artificial pancreas that enables type 1 diabetics to maintain stable blood sugar without injecting insulin, and a wrist watch that sounds an alarm if the wearer is at high risk of an impending heart attack.
In what could turn out to be his greatest achievement to date, SEF Chemo is the result of over three decades of research.
Drugs companies and oncologists turn their back
Impressed with Dr. Matsumara's credentials, as well as laboratory and animal research demonstrating cures of advanced cancers in a short period of time, the Food and Drug Administration (FDA) approved his first clinical trial in a record-breaking four days instead of the usual 12 months.
But his small research facility wasn't equipped, nor did his group have the finance to push forward his findings speedily, so he approached large pharmaceutical corporations for help.
The enthusiasm and support he expected was not forthcoming. They were not interested in a treatment that works so well and so quickly.
He writes:
"My naivety and trust in the world changed when I realized that a cancer cure is not good news for oncologists and hospitals because they financially depend on cancer treatment revenue.
"Imagine a cancer-free world in the eyes of someone who has dedicated their life -- years of education, allocation of resources and funds -- only to find your career obsolete.
"I have actually encountered oncologists who praised SEF Chemo and then suddenly reverse their support when the realization hit that their job, livelihood, and future could be challenged."
To the everlasting shame of our dysfunctional medical system, lack of support has delayed the availability of SEF Chemo by more than two decades.
Real-life patients get results
It wasn't until 2006 that the first small human trial began. Six late-stage cancer patients were enrolled. Results were reported in 2010. Of the six, four achieved total remission with no detectable cancer. These included a breast cancer patient with liver metastasis and others with lung cancer and leukemia.
For reasons that are not clear, Dr. Matsumara decided not to publish the results of this trial.
From all his work with patients he reports a response rate of almost 90% for stage 3 and early stage 4 cancers. These include colon cancer with extensive spread to the liver, and pancreatic cancer with liver metastasis.
Strong efficacy has been reported in non-small cell lung, breast, colorectal, prostate, cervical, melanoma and pancreatic cancer.
According to Dr. Matsumara, "The new therapy appears to be consistently reliable and far superior to anything else available today. Only time will tell if our long-term remissions will turn into cures."
When such findings come from a single lab with nothing published, we need to be wary, especially as Dr. Matsumara is something of a maverick.
But there are strong reasons to believe his findings are authentic. That's because he approached another cancer center located in Canada to adopt his therapy and witness the results for themselves.
SEF Chemo comes to Canada
Dr. Akbar Khan is the medical director of Medicor Cancer Centres, based in Ontario. They use a range of non-toxic and innovative "alternative" cancer therapies.
Reviewing the internal patient data of The Alin Foundation convinced Dr. Khan that SEF Chemo had merit, so it was introduced in 2013.
Response rate in the first 20 patients, most of them stage 4, was 80%. With adjustments to the protocol, today this has risen to 90%, up to five times higher than conventional chemotherapy. (Response generally means shrinkage of the tumor, not remission.)
Dr. Khan reports strong responses in lung, breast, melanoma, pancreatic, ovarian, cervical, prostate, liposarcoma, and non-Hodgkin's lymphoma. It's also been used successfully with glioblastoma.
In Dr. Khan’s opinion, "Complete remission is possible, especially for patients with low disease bulk (even if they are stage 4).
"For example, one of our early SEF patients with stage 4 cervical cancer spread to the abdomen and lungs achieved complete remission as determined by clear scans, normal tumor markers, and circulating tumor cell count of 0, performed three months after therapy completion.
"She received no conventional cancer therapy along with SEF."
For those with greater disease bulk, combining SEF Chemo with other non-toxic therapies can produce near-remission with long-term cancer stability.
What makes SEF Chemo so special
The concept of a drug that mitigates the adverse side effects of chemo is not entirely new. There are FDA approved antidotes for many cancer drugs.
Under certain procedures, these can almost completely eliminate the side effects of chemotherapy while maintaining its efficacy. The use of such an antidote allows stronger doses of the cancer-killing medication to be used, with the hope of thoroughly eradicating the evil beast.
With conventional chemotherapy, a much smaller percentage of tumor cells are directly killed, leaving survivlng cells to repair, multiply and spread.
On top of this, conventional chemo destroys important immune cells in the bone marrow called neutrophils. These can no longer seek out and extinguish damaged cancer cells.
SEF Chemo protects neutrophils – meaning the immune system is less damaged -- and thereby amplifies the therapy's effectiveness.
With a much higher kill rate and improved immunity, this "chemo-immunotherapy" causes tumors to shrink in weeks rather than months as in conventional treatment.
The SEF protocol
In a straightforward case, the chemotherapy drug carboplatin is used at the same time as its antidote mesna. The doctor administers carboplatin at 80% of the usual dose, but up to twice as often.
It’s an exaggeration to say the treatment is side-effect-free, but feelings of mild nausea or fatigue are usually gone in three or four days. There may also be some discomfort due to inflammation around the area of the tumor.
In practice, other chemo and non-chemo drugs may be added to allow for a more effective therapy.
The standard schedule is four days of intravenous treatment given on a fortnightly cycle. Carboplatin is infused on one of these days for about three hours. The mesna infusions take five minutes each.
The patient’s progress is assessed after three cycles. Therapy is usually completed in eight to ten weeks, but ten to 15 cycles may be needed for remission of stage 3 or stage 4 cancers.
Often, patients are able to continue working almost full time.
In 2016, a new, more gentle protocol was introduced for patients who have low cell counts and whose bone marrow has already been compromised by traditional chemotherapy.
Taming the chemo beast
In the alternative medical community, there's a strong antipathy to chemotherapy, and with good reason. It destroys the immune system, and the side effects are so dreadful, many patients decide after two or three rounds they’d rather die.
It doesn't even work for the vast majority of late-stage cancer patients (about 98%, says one study), AND the treatment itself can cause cancer.
SEF Chemo, while not entirely free of side effects, combats the negatives of traditional chemotherapy. It turns a hazardous and dangerous drug into a treatment that may be effective for some patients.
Dr. Matsumara hopes to train more doctors so that a more pleasant and effective form of chemo becomes available in other medical centers around the world.
My take is that this sounds worth trying for cancer patients who are afraid to rely solely on alternative treatments and feel they MUST do chemo. Many cancer patients also find themselves under intense pressure from family members to just "do what the doctor say," i.e. conventional chemo.
The Matsumara technique, combined with a regimen of supplements, healthy eating, detoxing, counseling, de-stressing and other alternative treatments, might be a good halfway house for these patients.
At this point, I don’t know of a place besides the Canadian clinic that offers it. Their contact information is:
Medicor Cancer Centres
4576 Yonge St, Suite 301,
Toronto, ON Canada M2N 6N4
tel (416) 227-0037 fax (416) 227-1915
Best regards,
Lee Euler,
Publisher
